NCT04582552

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

A Real-world Study of Clinical Markers for PARP Inhibitors in Epithelial Ovarian Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: Xiaoxiang Chen · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. PARP inhibitors(PARPi) are an important progress in EOC treatment. The available evidence suggests that BRCAmt or HRD-positive is an effective biological marker for PARPi. However, in our previous clinical observation, it was found that the tumor burden may be the potential clinical markers PARPi. We intend to develop a real-world study to confirm the potential clinical markers and explore new clinical markers for PARPi.

Detailed description

This study intends to conduct a systematic real-world study to observe the relationship between the clinical characteristics of EOC patients and the efficacy of PARPi based on our existing research foundation and stratified analyse these correlations by BRCA and HRD status.

Conditions

• Ovarian Cancer
• Clinical Marker
• PARP Inhibitor

Interventions

Type	Name	Description
DRUG	PARP inhibitors	Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.

Timeline

• Start date: 2020-12-15
• Primary completion: 2022-05-01
• Completion: 2023-11-01
• First posted: 2020-10-09
• Last updated: 2021-01-20

Locations

1 site across 1 country: China